G
General Oncology
General Oncology is developing innovative drug therapies for cancers
About General Oncology
General Oncology is a pioneering biopharmaceutical company focused on developing innovative drug therapies for various types of cancer, including solid metastatic cancers and cancers of the blood. The company aims to create treatments that are effective yet exhibit low toxicity to patients, thereby improving their quality of life during treatment.
General Oncology operates in the highly specialized oncology market, serving patients who are battling advanced stages of cancer. The company is currently sponsoring a clinical trial, Clinical Trial GO 1, which is investigating a treatment for BRCA-related metastatic pancreatic cancer. This treatment involves a combination of chemotherapy drugs—melphalan, BCNU, vitamin B12b, and vitamin C—along with two stem cell transplants to counteract bone marrow suppression. The trial is in Phase 1 and is open for enrollment.
The business model of General Oncology revolves around the research, development, and clinical testing of novel cancer treatments. Revenue is primarily generated through partnerships, grants, and eventually, the commercialization of successful therapies. By focusing on innovative solutions and clinical trials, General Oncology aims to bring new, effective treatments to market, addressing unmet medical needs in oncology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Brookline, United States
- Employees
- 8
- Open positions
- 1
- Dealroom signal
- 52.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Oncology, Drug Development, Stem Cells, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCEquity / VC | Nov 2021 | $2.3M | $9.2M | Undisclosed | — |
| EARLY VC✓Equity / VC | Sep 2017 | $35M | $139M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for General Oncology is 310 monthly website visits, down 42.6% over the last three months. General Oncology's team grew 14.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
General Oncology in the Brookline ecosystem
The General Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about General Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See General Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









